Gemphire Therapeutics Announces Expected Closing Date of Merger with NeuroBo Pharmaceuticals
30 déc. 2019 11h08 HE
|
Gemphire Therapeutics Inc.
ANN ARBOR, Mich., Dec. 30, 2019 (GLOBE NEWSWIRE) -- The pending merger between Gemphire Therapeutics Inc. (NASDAQ:GEMP) and NeuroBo Pharmaceuticals, Inc. is currently expected to close after market...
Gemphire Therapeutics Announces Stockholder Approval of Proposals Required for Merger with NeuroBo Pharmaceuticals
06 déc. 2019 08h42 HE
|
Gemphire Therapeutics Inc.
ANN ARBOR, Mich., Dec. 06, 2019 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP) announced today that, based upon the final vote count certified by the independent inspector of elections...
Gemphire Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update
09 août 2019 08h00 HE
|
Gemphire Therapeutics Inc.
LIVONIA, Mich., Aug. 09, 2019 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company developing and commercializing therapies for the treatment of...
Gemphire Therapeutics와 NeuroBo Pharmaceuticals, 퇴행성 질환 치료제 개발 위한 통합 법인 설립 위해 합병 합의
26 juil. 2019 06h01 HE
|
Gemphire Therapeutics Inc.
Nasdaq 상장사이자 NeuroBo의 임상단계 파이프라인 발전시킬 바이오 기술기업 탄생 NeuroBo, 신경병적 통증 치료 신약 후보 임상3상 시험 예정 NeuroBo, 최근 Series B 파이낸싱 통해 약 2,424만 달러 조달 Gemphire, 중국 시장 겨냥해 Beijing SL Pharmaceutical Co.와Gemcabene에 대한...
Gemphire Therapeutics and NeuroBo Pharmaceuticals Announce Merger Agreement to Advance a Neurodegenerative Disease Company
26 juil. 2019 06h01 HE
|
Gemphire Therapeutics Inc.
Transaction to Create Nasdaq-listed Biotechnology Company Focused on Advancing NeuroBo’s Clinical-Stage Pipeline NeuroBo Poised to Advance Lead Drug Candidate into Phase 3 Trials for Neuropathic Pain...
Gemphire Therapeutics and NeuroBo Pharmaceuticals Announce Merger Agreement to Advance a Neurodegenerative Disease Company
24 juil. 2019 16h01 HE
|
Gemphire Therapeutics Inc.
Transaction to Create Nasdaq-listed Biotechnology Company Focused on Advancing NeuroBo’s Clinical-Stage Pipeline NeuroBo Poised to Advance Lead Drug Candidate into Phase 3 Trials for Neuropathic Pain...
Gemphire Announces Top-Line Data from Familial Partial Lipodystrophy (FPLD) Phase 2a Proof-of-Concept NAFLD/NASH Clinical Trial
26 juin 2019 08h00 HE
|
Gemphire Therapeutics Inc.
LIVONIA, Mich., June 26, 2019 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ: GEMP) today announced top-line results based upon the Company’s preliminary review of the limited top-line...
Gemphire Therapeutics Reports Fourth Quarter and Fiscal Year 2018 Financial Results
15 mars 2019 08h00 HE
|
Gemphire Therapeutics Inc.
LIVONIA, Mich., March 15, 2019 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the...
Gemphire Therapeutics Announces Review of Strategic Alternatives and Provides Corporate Update
03 déc. 2018 08h00 HE
|
Gemphire Therapeutics Inc.
LIVONIA, Mich., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ: GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for...
Gemphire Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update
08 nov. 2018 16h01 HE
|
Gemphire Therapeutics Inc.
LIVONIA, Mich., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ: GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for...